WTA and Stats Perform Serve up Breakthrough Tennis AI and Data Partnership, in Landmark Deal for Women’s Sports
24.11.2020 16:00:00 EET | Business Wire | Press release
The WTA (Women’s Tennis Association) today named Stats Perform its Official WTA Data Supplier.
The transformative partnership will deliver multiple feeds to customers - an exclusive umpire-derived data feed for an expanded number of WTA matches, as well as an ultrafast data feed collected by Stats Perform’s Opta analysts.
The data collected by Stats Perform’s Opta analysts will include detailed match statistics down to rally and shot level. This will dramatically increase the level of live insight available for thousands of WTA matches to power a new range of broadcast, second screen, and betting experiences.
The data feed will support Stats Perform’s advanced AI capabilities which will be leveraged to help bring fans closer to the sport through engaging data-driven insights and stories. Through these unique insights, fans will be able to get to know the players and the game at a much deeper level.
The data also enhances Stats Perform’s existing live WTA video streaming service to help create the ultimate experience in trusted and entertaining in-play betting.
Stats Perform’s extensive sports content distribution capabilities will improve the availability of official WTA data to make it more accessible for authorized sportsbooks, broadcasters, OTT, media, sponsors, tech and fantasy games, giving fans and bettors fast, detailed and accurate tennis data.
As evidence of Stats Perform’s commitment to growing the profile of women athletes, the partnership will push more innovative insights and content to raise the profile of WTA players. The agreement also aims to elevate the betting experience through the delivery of faster, deeper feeds, and promote integrity in tennis via the provision of two operationally independent feeds.
Carl Mergele, CEO Stats Perform, says: “The WTA has very ambitious goals for their tournaments and players and we’re proud to be trusted to help them reach new levels of fan and bettor engagement. Our broadcaster, media, and betting networks are already excited because they’ve seen how high-quality information elevates sport’s appeal.”
Micky Lawler, WTA President, says: “Stats Perform has a history of creating innovative and trusted content and products that drive entertainment levels and new revenue streams for the professional sports ecosystem. We’re looking forward to discovering new and unique storylines surrounding the WTA Tour and our players and tournaments available in new, exciting and comprehensive ways.”
Atop its sports AI and content expertise and customer network, Stats Perform’s globally famous and trusted Opta data brand has helped it transform the way fans and bettors interact with men’s and women’s soccer, cricket, rugby, basketball, NFL and MLB. The company has a long history of challenging how sport is measured, giving players, teams and leagues a competitive edge and broadcasters, media, sportsbooks and sponsors new perspectives. Women’s tennis is now also set to see a rise in the profile of and engagement with the Tour and its players.
About Stats Perform
Stats Perform is the market leader in SportsTech providing the most trusted sports data and the latest advancements in applying AI and machine learning to deliver better predictions for teams, sportsbooks and a more engaging broadcast, media and fan experience. The company collects the most detailed sports data to create new experiences across sports. Leveraging the richest sports database, Stats Perform enhances sports competition and entertainment through machine learning and computer vision to create advanced predictions and analysis – be that for digital and broadcast media with differentiated storytelling, tech companies with reliable and fast data to power their innovations, sportsbooks with in-play betting and integrity services, or teams with first-of-its-kind AI analysis software. SportsContentCo is the exclusive reseller of Stats Perform premium sports betting content to licensed sportsbooks in the United States. For more information, visit StatsPerform.com or SportsContentCo.com.
About WTA
Founded by Billie Jean King in 1973 on the principle of equal opportunity for women in sports, the WTA is the global leader in women’s professional sport with more than 1,650 players representing 84 nations competing for a record $180 million in prize money. In 2019, the WTA was watched by a record-breaking global audience of 700 million. The 2020 WTA Tour includes 53 events and four Grand Slams, spanning across six continents and 28 countries and regions. The season culminates with the Shiseido WTA Finals Shenzhen, offering a $14 million total prize purse and honoring the season’s top singles and doubles players. Further information on the WTA can be found at www.wtatennis.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201124005368/en/
Contact information
Sarah Butler, Stats Perform PR Manager
Sarah.butler@statsperform.com / +44 07432631237
Amy Binder, WTA, abinder@wtatennis.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 14:00:00 EEST | Press release
CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which was confirmed by the study’s independent DSMB (Data and Safety Monit
Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint ® and BluePrint ® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 14:00:00 EEST | Press release
Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors – a group that typically has favorable outcomes. MammaPrint (MP) identified a High Risk 2 (H2) subset, representing 10% of all patients and 5% of those
The Biggest Predictor of Business Growth Is Behavior30.4.2026 10:00:00 EEST | Press release
IDEO, the global design and innovation company, today announced the IDEO Innovation Quotient (IDEO IQ), a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. Those with the highest IDEO IQ scores earned nearly $20 billion in profit last year—50% higher than average and three times more than those ranked at the bottom. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429978890/en/ The IDEO Innovation Quotient (IDEO IQ) is a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. The IDEO IQ surveyed 266 leaders in product and innovation roles at 100 of the world’s largest companies across the Media & Technology, Healthcare, and Consumer Goods sectors. The report is the first of its kind to draw a direct line between how companies operate internally and their financial performance. Companies were surve
Suzano Sells 12.7 Million Tonnes of Pulp for the First Time in Its History30.4.2026 01:22:00 EEST | Press release
Suzano(B3: SUZB3 | NYSE: SUZ), the world’s largest pulp producer, announces its results for the first quarter of 2026 (1Q26), achieving a new all‑time record in pulp sales. Over the 12‑month period from April 2025 to March 2026, the company sold 12.7 million tonnes of pulp, the highest volume ever recorded in its history. During the same period, Suzano also sold 1.7 million tonnes of paper across the packaging, printing and writing, specialty, and tissue segments. This unprecedented sales level mainly reflects the increase in production capacity following the start‑up of the Ribas do Rio Pardo pulp mill in the state of Mato Grosso do Sul, as well as Suzano’s strong operational efficiency across its production lines and supply chains, serving customers in more than 100 countries worldwide. In the first quarter of 2026, Suzano sold a total of 3.2 million tonnes, comprising 2.8 million tonnes of pulp and 378 thousand tonnes of paper. Net revenue amounted to BRL 11.0 billion, while adjuste
The Estée Lauder Companies Announces Minority Investment in Luxury Clinical Skin Care Brand 111SKIN29.4.2026 23:30:00 EEST | Press release
The Estée Lauder Companies Inc. (NYSE:EL) today announced a minority investment in 111SKIN, a luxury clinical skin care brand founded by renowned plastic and reconstructive surgeon Dr. Yannis Alexandrides. Terms of the investment were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429495879/en/ 111SKIN's Reparative Collection Founded in 2012, 111SKIN was originally developed by Dr. Alexandrides to accelerate his patients’ healing time following procedures. At the heart of the brand is its innovative NAC Y2™, a pioneering complex designed to support skin repair and maintain a healthy, radiant and resilient complexion. Building on the foundation of this clinical expertise, 111SKIN has developed a portfolio of more than 30 products, anchored by its Black Diamond and Reparative collections and priced from $50 to $1,000. “Skin care is entering a new phase, shaped by the convergence of procedures, longevity and b
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom